InsiderTrades.com logo
Stephen J. Hill net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Stephen Hill Biography and Net Worth

COO of Lyell Immunopharma

Stephen Hill has served as our Chief Operating Officer since October 2021. He joined Lyell in June 2019 as our Chief Technical Operations Officer. From June 2018 to June 2019, he was Senior Vice-President, Head of Global Biologics Operations and from March 2016 to June 2018 as Vice-President, Site Head at AstraZeneca, a publicly-traded company. From December 2012 through February 2016, Mr. Hill served in multiple positions at Amgen, including as Vice President, Bulk Manufacturing, Executive Director, Plant Manager and Executive Director, Manufacturing Technologies. Mr. Hill received an MBA and a B.S. in Microbiology and B.A. in Political Science from the University of Washington.

What is Stephen J. Hill's net worth?

The estimated net worth of Stephen J. Hill is at least $374.67 thousand as of February 11th, 2026. Hill owns 17,795 shares of Lyell Immunopharma stock worth more than $374,674 as of March 26th. This net worth evaluation does not reflect any other investments that Hill may own. Learn More about Stephen J. Hill's net worth.

How do I contact Stephen J. Hill?

The corporate mailing address for Hill and other Lyell Immunopharma executives is , , . Lyell Immunopharma can also be reached via phone at 650-695-0677 and via email at [email protected]. Learn More on Stephen J. Hill's contact information.

Has Stephen J. Hill been buying or selling shares of Lyell Immunopharma?

In the last ninety days, Stephen J. Hill has sold $31,430.12 of Lyell Immunopharma stock. Most recently, Stephen J. Hill sold 1,236 shares of the business's stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a transaction totalling $28,910.04. Following the completion of the sale, the chief operating officer now directly owns 17,795 shares of the company's stock, valued at $416,225.05. Learn More on Stephen J. Hill's trading history.

Who are Lyell Immunopharma's active insiders?

Lyell Immunopharma's insider roster includes Otis Brawley (Director), Otis Brawley (Director), Stephen Hill (COO), Richard Klausner (Director), Richard Klausner (Founder & Board Chair), Gary Lee (Insider), Charles Newton (CFO), Charles Newton (CFO), Sumant Ramachandra (Director), Lynn Seely (President & Chief Executive Officer), and Lynn Seely (CEO). Learn More on Lyell Immunopharma's active insiders.

Are insiders buying or selling shares of Lyell Immunopharma?

In the last twelve months, Lyell Immunopharma insiders bought shares 1 times. They purchased a total of 1,782 shares worth more than $19,958.40. In the last twelve months, insiders at the sold shares 19 times. They sold a total of 13,710 shares worth more than $294,348.44. The most recent insider tranaction occured on February, 11th when CEO Lynn Seely sold 7,455 shares worth more than $174,372.45. Insiders at Lyell Immunopharma own 22.3% of the company. Learn More about insider trades at Lyell Immunopharma.

Information on this page was last updated on 2/11/2026.

Stephen J. Hill Insider Trading History at Lyell Immunopharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/11/2026Sell1,236$23.39$28,910.0417,795View SEC Filing Icon  
2/10/2026Sell109$23.12$2,520.0819,031View SEC Filing Icon  
11/10/2025Sell95$16.12$1,531.4015,750View SEC Filing Icon  
8/12/2025Sell94$10.34$971.968,849View SEC Filing Icon  
8/11/2025Sell91$10.53$958.238,943View SEC Filing Icon  
See Full Table

Stephen J. Hill Buying and Selling Activity at Lyell Immunopharma

This chart shows Stephen J Hill's buying and selling at Lyell Immunopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lyell Immunopharma Company Overview

Lyell Immunopharma logo
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $20.49
Low: $19.90
High: $21.09

50 Day Range

MA: $23.37
Low: $19.12
High: $25.84

2 Week Range

Now: $20.49
Low: $7.65
High: $45.00

Volume

16,811 shs

Average Volume

103,804 shs

Market Capitalization

$477.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A